Amgen Inc. (NASDAQ:AMGN) Goldman Sachs forty sixth Annual World Healthcare Convention Name June 10, 2025 9:20 PM ET
Firm Members
James E. Bradner – Government Vice President of Analysis & Growth
Justin G. Claeys – Vice President of Investor Relations
Peter H. Griffith – Government VP & CFO
Convention Name Members
Salveen Jaswal Richter – Goldman Sachs Group, Inc., Analysis Division
Salveen Jaswal Richter
Nice. Good morning, everybody. Thanks a lot for becoming a member of us. I am actually happy to have with us the Amgen workforce at the moment. So subsequent to me is Jay Bradner, Head of R&D; Justin Claeys, Head of IR; and Peter Griffith, CFO. I am Salveen Richter, I cowl the biotechnology sector. Thanks for becoming a member of us. So to begin right here…
Justin G. Claeys
Perhaps peter can begin with just a few opening feedback, if that works. Peter, turning it over to you.
Peter H. Griffith
Thanks a lot. Salveen, thanks, and it is nice to be right here. It is nice to see you and the Goldman workforce, and we at all times respect the invitation. And look, good morning, and thank all of you for being with us at the moment. With the primary half of 2025 practically over, which I believe is stunning to all of us, we’re inspired by the momentum we have constructed throughout the enterprise.
First quarter revenues grew 9% and non-GAAP EPS elevated 24% year-over-year, supported by sturdy efficiency throughout the portfolio with 14 merchandise delivering double-digit development within the first quarter. Let me spotlight key drivers throughout the tip market merchandise and likewise throughout the quickly advancing pipeline. So let’s begin with normal drugs. Repatha is now a multibillion-dollar run price with Q1 2025 income up 27% to $665 million — excuse me, $656 million.
Heart problems stays a number one reason behind mortality worldwide, and we see continued sturdy development
